B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia

The aim of publication. To describe clinical case of development B-cell non-Hodgkin's lymphoma (В-NHL) in the patient with chronic hepatitis C, to demonstrate potential of concurrent treatment of В-NHL and viral infection, regression of lymphoma on a background of antiviral therapy.Summary. Pre...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. S. Adonyeva, Ye. A. Kolodyazhnaya, A. B. Bochkarev
Format:	Article
Language:	Russian
Published:	Gastro LLC 2015-03-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	hepatitis c non-hodgkin's lymphoma antiviral treatment
Online Access:	https://www.gastro-j.ru/jour/article/view/992
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Interfollicular Hodgkin’s lymphoma: A diagnostic challenge for pathologists
by: Maneesh K. Vijay, et al.
Published: (2023-03-01)

Use of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality
by: Alejandra Adriana Cardoso de Castro, et al.
Published: (2025-01-01)

PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW
by: Maria Luisa Moleti, et al.
Published: (2024-10-01)

Impact of Comorbidities on Prognosis and Treatment Outcomes in Elderly Patients with Hodgkin Lymphoma
by: Dávid Tóthfalusi, et al.
Published: (2025-01-01)

Breast Diffuse Large B-cell Lymphoma, Activated B-cell like Subtype: A Case Report
by: Sneha Samir Babaria, et al.
Published: (2025-01-01)

Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma
by: Ying Ni, et al.
Published: (2025-01-01)

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
by: Fanqiao Meng, et al.
Published: (2025-01-01)

Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy
by: Fazıl Çağrı Hunutlu, et al.
Published: (2025-01-01)

The prognostic value of ferritinemia level in patients with chronic hepatitis C
by: N. C. Sargsyants, et al.
Published: (2013-07-01)

Application of dicarbamin in treatment of patients by a chronic hepatitis C
by: D. Yu. Konstantinov, et al.
Published: (2011-09-01)

Modern modes of chronic hepatitis C treatment
by: V. T. Ivashkin, et al.
Published: (2012-02-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

Chronic hepatitis C course at elderly and therapeutic approach
by: M. V. Mayevskaya, et al.
Published: (2011-02-01)

Type B non-Hodgkin lymphoma in a patient with acquired immunodeficiency virus with no detected viral load. Case report
by: Edwin Marcelo Miranda Solìs, et al.
Published: (2023-07-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Integrated Approach for Biomarker Discovery and Mechanistic Insights into the Co-Pathogenesis of Type 2 Diabetes Mellitus and Non-Hodgkin Lymphoma
by: Zhu Y, et al.
Published: (2025-01-01)

Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP
by: Min Kyeong Kim, et al.
Published: (2016-12-01)

Modern modes of chronic hepatitis B treatment in daily clinical practice
by: M. V. Mayevskaya, et al.
Published: (2014-11-01)

Understanding the Molecular Mechanisms of Incomptine A in Treating Non-Hodgkin Lymphoma Associated with U-937 Cells: Bioinformatics Approaches, Part I
by: Fernando Calzada, et al.
Published: (2024-12-01)

Telaprevir in treatment of chronic hepatitis C: safety issues
by: T. M. Ignatova
Published: (2012-07-01)

Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non‐Hodgkin Lymphoma Patients
by: Wen Li, et al.
Published: (2024-12-01)

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
by: Guanghui Ren, et al.
Published: (2025-02-01)

Risk of progression and the cause of mortality at chronic viral mixed-hepatitis
by: K. I. Yesmembetov, et al.
Published: (2013-07-01)

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
by: Sarah R. Donaldson, et al.
Published: (2025-01-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C
by: S. N. Batskikh
Published: (2012-11-01)

Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review
by: Robert Gish, et al.
Published: (2025-01-01)

YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma
by: Aránzazu Chamorro-Jorganes, et al.
Published: (2025-03-01)

Chronic hepatitis B and risk of kidney involvement
by: M. V. Mayevskaya, et al.
Published: (2013-05-01)

Linfoma no Hodgkin. Reporte de un caso
by: Royland Bejerano Durán
Published: (2024-10-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C
by: N. B. Kovaleva
Published: (2014-08-01)

Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
by: Shams ElDoha Galal ElDin Zaiema, et al.
Published: (2025-01-01)

Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
by: Juferdy Kurniawan, et al.
Published: (2024-10-01)

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)

Inflammatory polyarthritis: It's Not always about the Joints!
by: Kavitha Mohanasundaram, et al.
Published: (2018-01-01)

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i>
by: A. V. Lapshin, et al.
Published: (2013-03-01)

Hypothesis: glyphosate-based herbicides can increase risk of hematopoietic malignancies through extended persistence in bone
by: Charles M. Benbrook
Published: (2025-01-01)

Hyperferritinemia at the patient with chronic hepatitis C
by: Ye. N. German, et al.
Published: (2009-02-01)

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)